Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ilan Bruchim

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|March 25, 2018
Impact of BRCA mutations on outcomes among patients with serous endometrial cancerYfat Kadan, Oshrat Raviv, Yakir Segev, et al.
Expert Opinion on Therapeutic Targets|February 8, 2024
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphereIlan Bruchim, Ilaria Capasso, Ariel Polonsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2011
BRCA1/2 germline mutations in Jewish patients with uterine serous carcinomaIlan Bruchim, Keren Amichay, Dvora Kidron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 26, 2013
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experienceTamar Safra, Tara Berman, Adelya Yachnin, et al.
Gynecologic Oncology|November 23, 2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancerWalter H Gotlieb, Ilan Bruchim, Jing Gu, et al.
Oncotarget|July 20, 2019
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancerLaris Achlaug, Rive Sarfstein, Karthik Nagaraj, et al.
Cancer Genetics and Cytogenetics|April 22, 2009
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinomaIlan Bruchim, Ofir Israeli, Salaheddin M Mahmud, et al.
Frontiers in Oncology|October 25, 2024
IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancerLina Somri-Gannam, Shilhav Meisel-Sharon, Shay Hantisteanu, et al.
Frontiers in Endocrinology|July 5, 2021
ZYG11A Is Expressed in Epithelial Ovarian Cancer and Correlates With Low Grade DiseaseLaris Achlaug, Lina Somri-Gannam, Shilhav Meisel-Sharon, et al.
Surgical Oncology|May 20, 2022
Predicting the rate of adjuvant postoperative chemo/radiation in cervical cancer with tumor size ≥2 cm and <4 cm: An Israeli Gynecologic Oncology Group studyOfer Gemer, Ahmet Namazov, Alon Ben-Arie, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
International Journal of Gynaecology and Obstetrics: the Official Organ of the International Federation of Gynaecology and Obstetrics|March 25, 2018
Impact of BRCA mutations on outcomes among patients with serous endometrial cancerYfat Kadan, Oshrat Raviv, Yakir Segev, et al.
Expert Opinion on Therapeutic Targets|February 8, 2024
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphereIlan Bruchim, Ilaria Capasso, Ariel Polonsky, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 6, 2011
BRCA1/2 germline mutations in Jewish patients with uterine serous carcinomaIlan Bruchim, Keren Amichay, Dvora Kidron, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 26, 2013
Weekly topotecan for recurrent ovarian, fallopian tube and primary peritoneal carcinoma: tolerability and efficacy study--the Israeli experienceTamar Safra, Tara Berman, Adelya Yachnin, et al.
Gynecologic Oncology|November 23, 2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancerWalter H Gotlieb, Ilan Bruchim, Jing Gu, et al.
Oncotarget|July 20, 2019
Identification of ZYG11A as a candidate IGF1-dependent proto-oncogene in endometrial cancerLaris Achlaug, Rive Sarfstein, Karthik Nagaraj, et al.
Cancer Genetics and Cytogenetics|April 22, 2009
Genetic alterations detected by comparative genomic hybridization and recurrence rate in epithelial ovarian carcinomaIlan Bruchim, Ofir Israeli, Salaheddin M Mahmud, et al.
Frontiers in Oncology|October 25, 2024
IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancerLina Somri-Gannam, Shilhav Meisel-Sharon, Shay Hantisteanu, et al.
Frontiers in Endocrinology|July 5, 2021
ZYG11A Is Expressed in Epithelial Ovarian Cancer and Correlates With Low Grade DiseaseLaris Achlaug, Lina Somri-Gannam, Shilhav Meisel-Sharon, et al.
Surgical Oncology|May 20, 2022
Predicting the rate of adjuvant postoperative chemo/radiation in cervical cancer with tumor size ≥2 cm and <4 cm: An Israeli Gynecologic Oncology Group studyOfer Gemer, Ahmet Namazov, Alon Ben-Arie, et al.
Pageof 9